Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q94535675)
Watch
English
Nivolumab: promising survival signal coupled with limited toxicity raises expectations
scientific article published on 3 March 2014
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
editorial
0 references
title
Nivolumab: promising survival signal coupled with limited toxicity raises expectations
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
author
Geraldine O'Sullivan Coyne
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
James L. Gulley
series ordinal
3
object named as
James L Gulley
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
author name string
Ravi A Madan
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
publication date
3 March 2014
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
published in
Journal of Clinical Oncology
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
volume
32
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
issue
10
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
page(s)
986-988
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
cites work
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Nivolumab plus ipilimumab in advanced melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6624830
retrieved
11 February 2021
Identifiers
DOI
10.1200/JCO.2013.54.5996
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
PMC publication ID
6624830
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
PubMed publication ID
24590655
1 reference
stated in
Europe PubMed Central
PMC publication ID
6624830
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6624830&resulttype=core&format=json
retrieved
15 May 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
